Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.

Lai KP, Chen J, He M, Ching AK, Lau C, Lai PB, To KF, Wong N.

Int J Cancer. 2014 Oct 15;135(8):1790-9. doi: 10.1002/ijc.28819. Epub 2014 Mar 11.

2.

Viral-human chimeric transcript predisposes risk to liver cancer development and progression.

Lau CC, Sun T, Ching AK, He M, Li JW, Wong AM, Co NN, Chan AW, Li PS, Lung RW, Tong JH, Lai PB, Chan HL, To KF, Chan TF, Wong N.

Cancer Cell. 2014 Mar 17;25(3):335-49. doi: 10.1016/j.ccr.2014.01.030. Epub 2014 Feb 27.

3.
4.

Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma.

Law PT, Qin H, Ching AK, Lai KP, Co NN, He M, Lung RW, Chan AW, Chan TF, Wong N.

J Hepatol. 2013 Jun;58(6):1165-73. doi: 10.1016/j.jhep.2013.01.032. Epub 2013 Jan 29.

PMID:
23376363
5.

GEF-H1 over-expression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling.

Cheng IK, Tsang BC, Lai KP, Ching AK, Chan AW, To KF, Lai PB, Wong N.

J Pathol. 2012 Dec;228(4):575-85. doi: 10.1002/path.4084. Epub 2012 Sep 28.

PMID:
22847784
6.

MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.

Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, Wong N.

Carcinogenesis. 2012 Jun;33(6):1134-41. doi: 10.1093/carcin/bgs130. Epub 2012 Mar 19.

PMID:
22431718
7.

A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.

Leung WK, Ching AK, Chan AW, Poon TC, Mian H, Wong AS, To KF, Wong N.

Oncogene. 2011 Nov 3;30(44):4464-75. doi: 10.1038/onc.2011.161. Epub 2011 May 16.

PMID:
21577206
8.

Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition.

Chung KY, Cheng IK, Ching AK, Chu JH, Lai PB, Wong N.

Hepatology. 2011 Jul;54(1):307-18. doi: 10.1002/hep.24372.

PMID:
21520196
9.

EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.

Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ.

Cancer Res. 2011 Jun 1;71(11):4028-39. doi: 10.1158/0008-5472.CAN-10-3342. Epub 2011 Apr 21.

10.

Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.

Zhou Q, Ching AK, Leung WK, Szeto CY, Ho SM, Chan PK, Yuan YF, Lai PB, Yeo W, Wong N.

Int J Oncol. 2011 Mar;38(3):721-31. doi: 10.3892/ijo.2011.902. Epub 2011 Jan 14.

PMID:
21240457
11.

Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers.

Leung WK, Ching AK, Wong N.

Mol Cell Biochem. 2011 Apr;350(1-2):201-6. doi: 10.1007/s11010-010-0699-8. Epub 2010 Dec 24.

PMID:
21184254
12.

MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling.

Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N.

Clin Cancer Res. 2010 Feb 1;16(3):867-75. doi: 10.1158/1078-0432.CCR-09-1840. Epub 2010 Jan 26.

13.

BRE over-expression promotes growth of hepatocellular carcinoma.

Chui YL, Ching AK, Chen S, Yip FP, Rowlands DK, James AE, Lee KK, Chan JY.

Biochem Biophys Res Commun. 2010 Jan 15;391(3):1522-5. doi: 10.1016/j.bbrc.2009.12.111. Epub 2009 Dec 24.

PMID:
20035718
14.

Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis.

Cheng IK, Ching AK, Chan TC, Chan AW, Wong CK, Choy KW, Kwan M, Lai PB, Wong N.

J Pathol. 2010 Feb;220(3):348-60. doi: 10.1002/path.2644.

PMID:
19927314
15.

miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1.

Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, Zhou L, Chen Z, Ng HK.

Hum Pathol. 2009 Sep;40(9):1234-43. doi: 10.1016/j.humpath.2009.02.003. Epub 2009 May 7.

PMID:
19427019
16.

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.

Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ, To KF.

Int J Cancer. 2009 Feb 1;124(3):644-52. doi: 10.1002/ijc.23968.

17.

Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice.

Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, Chan AW, Chong WW, Go MY, Yu J, To KF, Wang X, Chui YL, Fan DM, Sung JJ.

Carcinogenesis. 2008 Aug;29(8):1648-54. doi: 10.1093/carcin/bgn156. Epub 2008 Jul 7.

PMID:
18611916
18.

Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice.

Yu J, Wu CW, Chu ES, Hui AY, Cheng AS, Go MY, Ching AK, Chui YL, Chan HL, Sung JJ.

Biochem Biophys Res Commun. 2008 Aug 8;372(4):571-7. doi: 10.1016/j.bbrc.2008.05.069. Epub 2008 May 27.

PMID:
18503750
19.

BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma.

Chan BC, Ching AK, To KF, Leung JC, Chen S, Li Q, Lai PB, Tang NL, Shaw PC, Chan JY, James AE, Lai KN, Lim PL, Lee KK, Chui YL.

Oncogene. 2008 Feb 21;27(9):1208-17. Epub 2007 Aug 20.

PMID:
17704801
20.

Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis.

Yu J, Hui AY, Chu ES, Cheng AS, Go MY, Chan HL, Leung WK, Cheung KF, Ching AK, Chui YL, Chan KK, Sung JJ.

Gut. 2007 Jul;56(7):991-9. Epub 2006 Dec 5.

21.

Comparative proteomic analysis reveals a function of the novel death receptor-associated protein BRE in the regulation of prohibitin and p53 expression and proliferation.

Tang MK, Wang CM, Shan SW, Chui YL, Ching AK, Chow PH, Grotewold L, Chan JY, Lee KK.

Proteomics. 2006 Apr;6(8):2376-85.

PMID:
16518872
22.

BRE enhances in vivo growth of tumor cells.

Chan BC, Li Q, Chow SK, Ching AK, Liew CT, Lim PL, Lee KK, Chan JY, Chui YL.

Biochem Biophys Res Commun. 2005 Jan 14;326(2):268-73.

PMID:
15582573
23.

A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway.

Li Q, Ching AK, Chan BC, Chow SK, Lim PL, Ho TC, Ip WK, Wong CK, Lam CW, Lee KK, Chan JY, Chui YL.

J Biol Chem. 2004 Dec 10;279(50):52106-16. Epub 2004 Oct 1.

24.

Expression of a conserved mouse stress-modulating gene, Bre: comparison with the human ortholog.

Ching AK, Li Q, Lim PL, Chan JY, Chui YL.

DNA Cell Biol. 2003 Aug;22(8):497-504.

PMID:
14565866
25.

Expression of human BRE in multiple isoforms.

Ching AK, Li PS, Li Q, Chan BC, Chan JY, Lim PL, Pang JC, Chui YL.

Biochem Biophys Res Commun. 2001 Nov 2;288(3):535-45.

PMID:
11676476
26.

Strand bias in Ig somatic hypermutation is determined by signal sequence within the variable region.

Ching AK, Li PS, Chan WY, Ma CH, Lee SS, Lim PL, Chui YL.

Int Immunol. 2000 Sep;12(9):1245-53.

PMID:
10967019
27.

Strand breaks in immunoglobulin gene hypermutation.

Lo AK, Ching AK, Lim PL, Chui YL.

Ann N Y Acad Sci. 1997 Apr 5;815:432-5. No abstract available.

PMID:
9186690
28.

BibleCard: network-based virtual database for laboratory information.

Fine JS, Ching AK, Schneider JB, Pollum D, Astion ML.

Clin Chem. 1995 Sep;41(9):1349-53. Review.

29.

Cytoplasmic tutor: a program for teaching interpretation of a microscope-based laboratory test.

Astion ML, Hutchinson K, Ching AK, Pagliaro LJ, Wener MH.

MD Comput. 1994 Sep-Oct;11(5):301-6.

PMID:
7968388

Supplemental Content

Loading ...
Support Center